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Take home message 
In asthmatics with a preserved FEV1, small airways dysfunction defined by FEF25-75 and R5-
R20 was associated with poorer long-term control. 
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Small Airways Dysfunction is Associated with Poorer Asthma Control   
The clinical relevance of the small airways in persistent asthma has been gaining greater 
recognition in recent years [1]. Studies have shown that a significant proportion of asthmatics 
on standard treatment fail to achieve satisfactory asthma control. For example, in one study of 
3421 asthmatic subjects who underwent guideline driven dose titration with standard inhaled 
corticosteroids (ICS) / long-acting beta-agonist (LABA) combination therapy over 1 year, 
only 41% achieved total control of their asthma while 71% were well controlled [2]. 
Anderson et al [3]
 
found a high prevalence of adult patients with persistent small airway 
dysfunction determined by impulse oscillometry (IOS, as R5-R20) and spirometry (as FEF25-
75) across British Thoracic Society (BTS) treatment steps for asthma, many of whom had a 
preserved FEV1. This in turn suggests an unmet clinical need in terms of patients who may 
have a small airway asthma phenotype. 
We therefore evaluated whether small airways dysfunction was associated with worse control 
in adult asthmatics with a preserved FEV1 (FEV1 > 80% predicted). Spirometry and IOS 
measurements from unselected asthmatics referred from primary care who attended for 
screening visits for clinical trials were linked to prescription data. The prescription data were 
obtained from the Tayside Health Informatics Centre which links all community dispensed 
prescriptions using a person’s unique identifier, the Community Health Index. Spirometry 
and IOS measurements from asthmatics were linked to oral corticosteroid and short-acting 
beta-agonist (SABA) use. We evaluated if small airways dysfunction, defined as FEF25-75 < 
70%, or peripheral airway resistance as R5-R20 > 0.07 kPa·L
-1
·s was associated with 
increased oral corticosteroid and SABA use. Oral steroid and SABA use 1 year prior and 1 
year following the index measurements were determined i.e. whether or not patients had an 
oral steroid prescription for an asthma exacerbation or the use of  > 4 or ≤ 4 SABA inhalers. 
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 Research ethics committee approval was obtained for all the studies the patients were being 
screened into and Caldicott Guardian approval was obtained to transfer the data to the Health 
Informatics Centre. IOS (Jaeger Masterscreen IOS, Hochberg, Germany) was performed in 
triplicate in accordance with manufacturer’s guidelines. A SuperSpiro spirometer (Micro 
Medical Ltd., Chatham, Kent, United Kingdom) was used in triplicate in accordance with 
European Society guidelines [4]. Logistic regression analysis was applied to calculate the 
odds ratios (OR) for steroid and salbutamol use in the different groups. Age, gender, ICS, 
LABA and leukotriene receptor antagonists (LTRA) use were all included as covariates to 
calculate the adjusted OR and 95% confidence interval. 
302 out of 442 (68%) asthmatics had a preserved FEV1 > 80%, mean age: 40 years, FEV1: 
97%, median ICS dose: 800µg, 42% taking LABA, 22% on LTRA and 5% on theophylline. 
The proportion of patients at BTS treatment steps 1-4 were 6.3%, 37.7%, 27.8 % and 28.0 % 
respectively .The results in Table 1 showed that persistent small airways dysfunction,  
defined by FEF25-75 and R5-20, was associated with a  significantly increased likelihood of  
having worse long-term asthma control. The risk of having poorer control was greater when 
measurements of FEF25-75 and R5-R20 were combined. However, adding in FEV1/FVC to the 
model did not appreciably improve the OR compared to the combined outcome of FEF25-75 
and R5-20 because FEV1/FVC and FEF25-75 were both highly correlated (r = 0.82, P < 0.001). 
When our analysis was corrected for factors including age, gender, ICS, LABA and LTRA, 
the adjusted OR for FEF25-75 and R5-20 were similar. R5% predicted (n=302) and resonant 
frequency (n=268) however, did not have a significant impact in determining asthma control. 
There were insufficient evaluable data to perform a meaningful analysis on reactance area 
(AX) (n=75). During the study period, in those with a preserved FEV1, there were a total of 
14 Emergency Department visits and 33 hospital admissions for asthma exacerbations. 
However, these numbers were too small to perform a meaningful analysis. 
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  Our results are similar to those of previously reported studies in asthmatic children by Shi et 
al [5] who showed a significant difference between selected cohorts of controlled and 
uncontrolled asthmatic children for both FEF25-75 and FEV1/ FVC, while peripheral resistance 
(R5-R20 > 0.15 kPa·L
-1
·s )  and reactance area (AX > 0.95 kPa·L
-1 
) were equally predictive 
for detecting control. In a prospective follow up study [6] of initially controlled asthmatic 
children, the same authors observed a significant difference in FEV1/FVC but not FEF25-75 at 
baseline, but for both FEV1/FVC and FEF25-75 at follow up after 3 months, comparing those 
who remained controlled to those who subsequently became uncontrolled.  Rao et al [7] in a 
similar design to the present study over 2 years using electronic prescribing linkage, 
compared matched groups of asthmatic children who had a preserved FEV1 (> 80%) with an 
abnormal FEV1/FVC (< 0.85) and FEF25-75 (< 60%) versus those with normal values, 
showing significantly increased OR for loss of control in terms of oral steroid use, asthma 
exacerbations and controller use.  
We elected to use cut-off thresholds for small airways measurements which provided the best 
compromise in terms of achieving balanced numbers of patients in each group from which to 
make informative comparisons.  Such cut-off values for normality are always going to be 
rather arbitrary whether they are more of less severe in nature. We acknowledge our data has 
some limitations in terms of it being a retrospective type health informatics study linked to a 
single index measurement of pulmonary function. However, we feel that our data more 
closely reflects real life practice where compliance is usually poor in the community. Our 
unselected cohort of persistent asthmatics were referred from primary care and reflected a 
wide spectrum of severity across BTS treatment steps.  
We feel that our study may have some important potential clinical implications.  It appears 
that effort independent (i.e. IOS ) and effort dependent measurements  (i.e. spirometry ) may 
provide distinct yet complimentary information on the  small airways phenotype, as shown by 
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 the higher OR for the composite of FEF25-75 and R5-R20 compared to either measurement  
alone.  
It remains unclear as to whether small airway markers may be improved by using extra fine 
particle inhaled therapy including currently available extra fine ICS and ICS/LABA 
formulations and how this relates to long-term asthma control. We also do not know if small 
airways dysfunction as reflected by abnormal FEF25-75 or R5-20 is due to ongoing persistent 
inflammation or simply altered airways geometry. Several prospective randomised controlled 
trials have shown greater improvements in small airways outcomes in response to extra fine 
compared to coarse particle ICS formulations in unselected patient cohorts [8-12]. Other 
retrospective health informatics data comparing extra fine and coarse particle ICS 
formulations have revealed consistent  results in terms of improved asthma control based on 
prescribing outcomes, but have not measured any small airway pulmonary function outcomes 
[13-15]. We believe the time has now come for designing prospective randomized controlled 
trials enrolling patients with an enriched small airways phenotype, perhaps powered on 
pragmatic outcomes such as the Asthma Control Questionnaire.  
In conclusion, we have shown that in adult asthmatics who have a preserved FEV1, the 
presence of persistent small airways dysfunction was associated with poorer control, perhaps 
suggesting the presence of a defined small airway asthma phenotype.  
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 Table 1 Odds ratio (95% CI) for small airway indices in 302 patients with FEV1 > 80% predicted   
 Crude odds ratio 
 
P value Adjusted odds ratio P value 
FEF25-75 < 70 %  n=157 versus FEF25-75  > 70%  n=145 
Oral steroid use 1.67 (1.04-2.68) 0.04 1.50 (0.91-2.48) 0.11 
SABA use 2.00 (1.27-3.16) 0.003 1.91 (1.19—3.07) 0.007 
FEV1/FVC < 0.80, n=167 versus FEV1/FVC > 0.80, n=135 
Oral steroid use 2.06 (1.27-3.35) 0.004 1.85 (1.10-3.12) 0.02 
SABA use 1.61 (1.02-2.54) 0.04 1.54 (0.95-2.51) 0.08 
 
R5-R20 > 0.07 kPa·L-1·s, n=135 versus R5-R20 < 0.07 kPa·L-1·s, n =167 
Oral steroid use 1.99 (1.23-3.19) 0.005 1.80 (1.09-2.98) 0.02 
SABA use 
 
1.83 (1.16-2.89) 0.01 1.87 (1.15-3.01) 0.01 
FEF25-75 < 70 %  & R5-R20 > 0.07 kPa·L
-1·s; n=83 versus FEF25-75  > 70%  & R5-R20 < 0.07 kPa·L
-1·s; n=93 
Oral steroid use 2.77 (1.48-5.18) 0.001 2.34 (1.20-4.58) 0.01 
SABA use 3.07 (1.66-5.67) <0.001 3.16 (1.64-6.07) 0.001 
     
FEF25-75 < 70 % , R5-R20 >0.07 kPa·L
-1·s & FEV1/FVC < 0.80; n=72 versus FEF25-75 > 70%  & 
R5-R20 < 0.07 kPa·L-1·s & FEV1/FVC > 0.80; n=75 
 
Oral steroid use 3.29 (1.64-6.61) 0.001 2.78 (1.28-6.04) 0.01 
SABA use 3.16 (1.61-6.19) 0.001 2.96 (1.44-6.12) 0.003 
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